FDA Novel Drug Approvals – June 2022

Jul 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Amvuttra vutrisiran 6/13/2022 To treat polyneuropathy of hereditary transthyretin-mediated

FDA Novel Drug Approvals – May 2022

Jun 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Vtama tapinarof 5/23/2022 To treat plaque psoriasis Drug Trials

FDA Novel Drug Approvals – April 2022

May 022022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Camzyos mavacamten 4/28/2022 To treat certain classes of obstructive

FDA Novel Drug Approvals – March 2022

Apr 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Pluvicto lutetium (177Lu) vipivotide tetraxetan 3/23/2022 To treat prostate-specific

FDA Novel Drug Approvals – February 2022

Mar 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Vonjo pacritinib 2/28/2022 To treat intermediate or high-risk primary

FDA Novel Drug Approvals – January 2022

Feb 012022
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Vabysmo faricimab-svoa 1/28/2022 To treat neovascular (wet) aged-related macular

 Newer Entries